Educational Videos

22 July 2025

Revolutionary CAR T-Cell Therapy for Multiple Myeloma: How it Works

22 July 2025

KappaMab Explained: A Breakthrough in Immunotherapy

19 June 2024

HaemaLogiX CSO Dr Rosanne Dunn explains the key highlights of the abstract that was recently published on the European Hematology Association (EHA)

1 June 2023

Inside the KappaMab manufacturing process

22 December 2022

What makes our immunotherapies different on the large and growing multiple myeloma treatment market

22 December 2022

The latest on our CAR-T technology and more, presented at Myeloma Australia’s 4th National Myeloma Workshop

21 December 2022

Novel antigens LMA and KMA are expressed on malignant bone marrow plasma cells from patients at all stages of multiple myeloma

15 August 2022

Chief Manufacturing and Development Officer Tertia Dex explains the KappaMab manufacturing process

15 March 2022

HaemaLogiX's Mary Sartor's presentation to the 63rd Annual ASH Annual Meeting in Atlanta, Georgia 2021

16 February 2022

How KappaMab works. KappaMab is a monoclonal antibody developed by HaemaLogiX to treat blood cancers, with an initial focus on multiple myeloma.